Bioxcel Therapeutics Inc (BTAI)

May 05, 2026

BioXcel Therapeutics, Inc. (BTAI) expected to beat earnings estimates: Should you buy? - MSN

May 05, 2026

May 04, 2026

BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

May 04, 2026

Apr 25, 2026

BioXcel Shareholder Action Reminder - TMX Newsfile

Apr 25, 2026

Apr 24, 2026

BioXcel Shareholder Notice - TMX Newsfile

Apr 24, 2026

Apr 24, 2026

BTAI Forecast, Price Target & Analyst Ratings | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill

Apr 24, 2026

Apr 23, 2026

BTAI: IGALMI targets a vast at-home market for acute agitation, with launch readiness for 2027 - TradingView

Apr 23, 2026

Apr 23, 2026

Transcript : BioXcel Therapeutics, Inc.Special Call - marketscreener.com

Apr 23, 2026

Apr 23, 2026

BTAI (BioXcel Therapeutics Inc.) reports narrower Q4 2025 loss than expected, shares gain 7.48 percent on upbeat investor reaction.NCAV - Xã Thanh Hà

Apr 23, 2026

Apr 22, 2026

BTAI BioXcel Therapeutics Inc. gains 7.48 percent after posting narrower than expected Q4 2025 EPS results. - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 22, 2026

Apr 22, 2026

BTAI Financials: Income Statement, Balance Sheet & Cash Flow | Bioxcel Therapeutics Inc - Stock Titan

Apr 22, 2026

Apr 18, 2026

BioXcel Therapeutics, Inc. Enters Fourth Amended and Restated Registration Rights Agreement With Oaktree Investors - Minichart

Apr 18, 2026

Apr 18, 2026

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting - Sahm

Apr 18, 2026

Apr 17, 2026

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI in the At-Home Setting - 富途牛牛

Apr 17, 2026

Apr 17, 2026

BioXcel Therapeutics issues warrants to lenders as part of credit agreement amendment - Investing.com

Apr 17, 2026

Apr 17, 2026

Bioxcel Issues Warrants in Private Equity Financing Deal - TipRanks

Apr 17, 2026

Apr 17, 2026

BioXcel Therapeutics (NASDAQ: BTAI) grants 1,353,729 low-price warrants - Stock Titan

Apr 17, 2026

Apr 17, 2026

BioXcel to detail IGALMI launch strategy ahead of FDA decision By Investing.com - Investing.com Australia

Apr 17, 2026

Apr 17, 2026

H.C. Wainwright Adjusts BioXcel Therapeutics, Inc. (BTAI) Outlook Following Capital Structure Concerns - Insider Monkey

Apr 17, 2026

Apr 17, 2026

BioXcel to detail IGALMI launch strategy ahead of FDA decision - Investing.com

Apr 17, 2026

Apr 13, 2026

How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Promise And Dilution Risks - Yahoo Finance

Apr 13, 2026

Apr 11, 2026

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Bioxcel Therapeutics (BTAI) - The Globe and Mail

Apr 11, 2026

Apr 10, 2026

H.C. Wainwright reiterates BioXcel Therapeutics stock rating at buy By Investing.com - Investing.com Canada

Apr 10, 2026

Apr 10, 2026

H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Apr 10, 2026

Apr 10, 2026

Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Finviz

Apr 10, 2026

Apr 09, 2026

Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary D - GuruFocus

Apr 09, 2026

Apr 09, 2026

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions - Sahm

Apr 09, 2026

Apr 09, 2026

BioXcel Therapeutics, Inc. (BTAI) Stock Price, News, Quote & History - Yahoo! Finance Canada

Apr 09, 2026

Apr 08, 2026

BioXcel Therapeutics, Inc. (BTAI) stock price, news, quote and history - Yahoo Finance Australia

Apr 08, 2026

Apr 08, 2026

Jobs Data: Is BioXcel Therapeutics Inc a strong candidate for buy and hold2026 Fundamental Recap & Safe Entry Zone Tips - baoquankhu1.vn

Apr 08, 2026

Apr 08, 2026

BioXcel Therapeutics announces enrollment of first patients in U.S. Department of War-funded study of BXCL501 (sublingual dexmedetomidine) for treatment of acute stress reactions - marketscreener.com

Apr 08, 2026

Apr 08, 2026

BioXcel begins DoW-funded trial of BXCL501 for acute stress By Investing.com - Investing.com Canada

Apr 08, 2026

Apr 08, 2026

BioXcel drug enters U.S. military-funded study for acute stress after trauma - Stock Titan

Apr 08, 2026

Apr 04, 2026

BTAI Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026

Apr 04, 2026

BioXcel Therapeutics Inc. (BX20.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore

Apr 04, 2026

Apr 04, 2026

BTAI Should I Buy - Intellectia AI

Apr 04, 2026

Apr 02, 2026

BTAI: HC Wainwright & Co. Lowers Price Target, Maintains Buy Rat - GuruFocus

Apr 02, 2026

Apr 02, 2026

H.C. Wainwright cuts BioXcel Therapeutics price target on dilution By Investing.com - Investing.com South Africa

Apr 02, 2026

Apr 02, 2026

H.C. Wainwright cuts BioXcel Therapeutics price target on dilution - Investing.com

Apr 02, 2026

Apr 02, 2026

H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Cuts Target Price to $5 - Moomoo

Apr 02, 2026

Apr 02, 2026

FDA accepts BioXcel filing for at-home agitation treatment By Investing.com - Investing.com South Africa

Apr 02, 2026

Apr 02, 2026

FDA accepts BioXcel filing for at-home use of agitation drug By Investing.com - Investing.com South Africa

Apr 02, 2026

Apr 02, 2026

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting - Sahm

Apr 02, 2026